Chatterjee, S., L. C. Heukamp, M. Siobal, J. Schöttle, C. Wieczorek, M. Peifer, D. Frasca, M. Koker, K. König, L. Meder, D. Rauh, R. Buettner, J. Wolf, R. A. Brekken, B. Neumaier, G. Christofori, R. K. Thomas and R. T. Ullrich: Tumor vegf:vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer. In: Journal of Clinical Investigation 123, 4, 1732-1740 (2013).
doi: 10.1172/JCI65385
Ohashi, K., L. V. Sequist, M. E. Arcila, C. M. Lovly, X. Chen, C. M. Rudin, T. Moran, D. R. Camidge, C. L. Vnencak-Jones, L. Berry, Y. Pan, H. Sasaki, J. A. Engelmann, E. B. Garon, S. M. Dubinett, W. A. Franklin, G. J. Riely, M. L. Sos, M. G. Kris, D. Dias-Santagata, M. Ladanyi, P. A. Bunn and W. Pao: Characteristics of lung cancers harboring NRAS mutations. In: Clinical Cancer Research 19, 9, 2584-2591 (2013).
doi: 10.1158/1078-0432.CCR-12-3173
Seidel, D., T. Zander, L. C. Heukamp, M. Peifer, M. Bos, L. Fernandez-Cuesta, F. Leenders, X. Lu, S. Ansen, M. Gardizi, C. Nguyen, J. Berg, P. Russell, Z. Wainer, H.-U. Schildhaus, T.-M. Rogers, B. Solomon, W. Pao, S. L. Carter, G. Getz, D. N. Hayes, M. D. Wilkerson, E. Thunnissen, W. D. Travis, S. Perner, G. Wright, E. Brambilla, R. Buettner, J. Wolf, R. Thomas, F. Gabler, I. Wilkening, C. Mueller, I. Dahmen, R. Menon, K. Koenig, K. Albus, S. Merkelbach-Bruse, J. Fassunke, K. Schmitz, H. Kuenstlinger, M. Kleine, E. Binot, S. Querings, J. Altmueller, I. Boessmann, P. Nuemberg, P. Schneider, M. Bogus, R. Buettner, A. Soltermann, H. Moch, O. T. Brustugun, S. Solberg, M. Lund-Iversen, A. Helland, T. Muley, H. Hoffmann, P. A. Schnabel, Y. Chen, H. Groen, W. Timens, H. Sietsma, J. H. Clement, W. Weder, J. Saenger, E. Stoelben, C. Ludwig, W. Engel-Riedel, E. Smit, D. A. M. Heideman, P. J. F. Snijders, L. Nogova, M. L. Sos, C. Mattonet, K. Toepelt, M. Scheffler, E. Goekkurt, R. Kappes, S. Krueger, K. Kambartel, D. Behringer, W. Schulte, W. Galetke, W. Randerath, M. Heldwein, A. Schlesinger, M. Serke, K. Hekmat, K. F. Frank, R. Schnell, M. Reiser, A.-N. Huenerlituerkoglu, S. Schmitz, L. Meffert, Y.-D. Ko, M. Litt-Lampe, U. Gerigk, R. Fricke, B. Besse, C. Brambilla, S. Lantuejoul, P. Lorimier, D. Moro-Sibilot, F. Cappuzzo, C. Ligorio, S. Damiani, J. K. Field, R. Hyde, P. Validire, P. Girard, L. A. Muscarella, V. M. Fazio, M. Hallek, J.-C. Soria, S. L. Carter, V. Achter and U. Lang: A genomics-based classification of human lung tumors. In: Science Translational Medicine 5, 209, Seq. No.: 209ra153 (2013).
doi: 10.1126/scitranslmed.3006802
Chmielecki, J., M. Peifer, A. Viale, K. Hutchinson, J. Giltnane, N. D. Socci, R. S. Dean, A. Yenamandra, M. Jagasia, A. S. Kim, U. P. Davé, R. K. Thomas and W. Pao: Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. In: Genes Chromosomes and Cancer 51, 1, 54-65 (2012).
doi: 10.1002/gcc.20930
Sos, M. L. and R. K. Thomas: Genetic insight and therapeutic targets in squamous-cell lung cancer. In: Oncogene 31, 46, 4811-4814 (2012).
doi: 10.1038/onc.2011.640
Thomas, R. K. and J. Wolf: Personalized therapy of lung cancer. In: Onkologie 35, Suppl. 1, 14-19 (2012).
doi: 10.1159/0003348276
Scheffler, M., C. Kobe, T. Zander, L. Nogova, D. Kahraman, R. K. Thomas, B. Neumaier, M. Dietlein and J. Wolf: Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET. In: Lung Cancer 77, 3, 617-620 (2012).
doi: 10.1016/j.lungcan.2012.05.110
Ohashi, K., L. V. Sequist, T. Moran, J. Chmielecki, Y.-L. Lin, Y. Pan, L. Wang, E. de Stanchina, K. Shien, K. Aoe, S. Toyooka, K. Kiura, L. Fernandez-Cuesta, P. Fidias, J. C.-H. Yang, V. A. Miller, G. J. Riely, M. G. Kris, J. A. Engelman, X. L. Vnencak-Jones, D. Dias-Santagata, M. Ladanyi and W. Pao: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. In: Proceedings of the National Academy of Sciences of the United States of America 109, 31, E2127-E2133 (2012).
doi: 10.1073/pnas.1203530109
Höpker, K., H. Hagmann, S. Khurshid, S. Chen, P. Hasskamp, T. Seeger-Nukpezah, K. Schilberg, L. Heukamp, T. Lamkemeyer, M. L. Sos, R. K. Thomas, D. Lowery, F. Roels, M. Fischer, M. C. Liebau, U. Resch, T. Kisner, F. Röther, M. P. Bartram, R. U. Müller, F. Fabretti, P. Kurschat, B. Schumacher, M. Gaestel, R. H. Medema, M. B. Yaffe, B. Schermer, H. C. Reinhard and T. Benzing: AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. In: EMBO Journal 31, 20, 3961-3975 (2012).
doi: 10.1038/emboj.2012.236
Heuckmann, J. M., H. Balke-Want, F. Malchers, M. Peifer, M. L. Sos, M. Koker, L. Meder, C. M. Lovly, L. C. Heukamp, W. Pao, R. Küppers and R. K. Thomas: Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. In: Clinical Cancer Research 18, 17, 4682-4690 (2012).
doi: 10.1158/1078-0432.CCR-11-3260
http://edoc.mpg.de
The Max Planck Society does not take any responsibility for the content of this export.